10q10k10q10k.net
Zenas BioPharma, Inc.

Zenas BioPharma, Inc.ZBIOEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

Zenas BioPharma is a global clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with autoimmune diseases and rare, unmet medical needs. Its pipeline covers multiple therapeutic modalities, with core markets spanning North America, the Asia-Pacific region, and Europe, targeting underserved patient populations that lack effective existing treatment options.

Q4 2025Q3 2025Q2 2025Q1 2025Q3 2024

ZBIO Q4 FY2025 Key Financial Metrics

Revenue

$0

Gross Profit

N/A

Operating Profit

N/A

Net Profit

N/A

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

YoY Growth

N/A

Zenas BioPharma, Inc. Q4 FY2025 Financial Summary

Zenas BioPharma, Inc. reported revenue of $0 for Q4 FY2025, with a net profit of N/A (N/A margin).

Key Financial Metrics

Total Revenue$0
Net ProfitN/A
Gross MarginN/A
Operating MarginN/A
Report PeriodQ4 FY2025

Zenas BioPharma, Inc. Annual Revenue by Year

Zenas BioPharma, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $10.0M).

YearAnnual Revenue
2025$10.0Mvs 2024 →

Zenas BioPharma, Inc. Quarterly Revenue & Net Profit History

Zenas BioPharma, Inc. results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q4 FY2025$0—N/AN/A
Q3 FY2025$0—$-51.5MN/A
Q2 FY2025$0—$-52.2MN/A
Q1 FY2025$10.0M—$-33.6M-335.7%
Q3 FY2024$0—$-38.6MN/A

Income Statement

Q3 2024Q1 2025Q2 2025Q3 2025Q4 2025
Revenue$0$10.0M$0$0$0
YoY GrowthN/AN/AN/AN/AN/A

Balance Sheet

Q3 2024Q1 2025Q2 2025Q3 2025Q4 2025
Assets$403.4M$333.8M$293.1M$322.0M$383.6M
Liabilities$44.0M$49.4M$53.5M$125.6M$141.5M
Equity$359.4M$284.3M$239.6M$196.4M$242.1M

Cash Flow

Q1 2025Q2 2025Q3 2025Q4 2025
Operating CF$-37.1M$-41.7M$-41.1M$-172.3M